FILINGS
| GLAXF 0001131399 | |||
|---|---|---|---|
| Filing Date | Form Type | Description | Document |
| 2025-06-18 | 11-K | ANNUAL REPORT OF EMPLOYEE STOCK PURCHASE | View Document |
| 2025-06-18 | 11-K | ANNUAL REPORT OF EMPLOYEE STOCK PURCHASE PLANS | View Document |
| 2025-06-18 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-06-17 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-06-16 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-06-13 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2025-06-13 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-06-13 | 6-K | GSK SUBMITS AREXVY FOR ADULTS 18+ WITH EMA | View Document |
| 2025-06-12 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2025-06-12 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-06-11 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2025-06-11 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-06-10 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-06-09 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-06-06 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-06-05 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-06-04 | 6-K | GSK - SECOND TRANCHE OF SHARE BUYBACK PROGRAMME | View Document |
| 2025-06-04 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-06-03 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-06-02 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2025-06-02 | 6-K | TOTAL VOTING RIGHTS | View Document |
| 2025-06-02 | 6-K | LINERIXIBAT FILE ACCEPTED FOR REVIEW BY US FDA | View Document |
| 2025-06-02 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-05-30 | SD | SPECIALIZED DISCLOSURE REPORT | View Document |
| 2025-05-30 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-05-29 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-05-28 | 6-K | GSK STOPS PHASE 3 TRIAL ON CUTIS FOR EFFICACY | View Document |
| 2025-05-28 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-05-27 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-05-23 | 6-K | POSITIVE CHMP OPINION ON BLENREP IN EU | View Document |
| 2025-05-23 | 6-K | FDA APPROVES NUCALA COPD INDICATION | View Document |
| 2025-05-23 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-05-22 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-05-21 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-05-20 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2025-05-20 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-05-19 | 6-K | BLENREP FOR 2L+ MULTIPLE MYELOMA APPROVED IN JAPAN | View Document |
| 2025-05-19 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-05-16 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-05-15 | 25-NSE | View Document | |
| 2025-05-15 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-05-14 | 6-K | GSK TO ACQUIRE EFIMOSFERMIN | View Document |
| 2025-05-14 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-05-13 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2025-05-13 | 6-K | UPDATE ON BELRESTOTUG DEVELOPMENT PROGRAMME | View Document |
| 2025-05-13 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-05-12 | 6-K | BLOCK LISTING INTERIM REVIEW | View Document |
| 2025-05-12 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-05-09 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-05-08 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2025-05-08 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2025-05-08 | 6-K | LINERIXIBAT GLISTEN PIII TRIAL DATA AT EASL | View Document |
| 2025-05-08 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-05-07 | 6-K | RESULT OF AGM | View Document |
| 2025-05-07 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-05-06 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-05-02 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-05-01 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2025-05-01 | 6-K | TOTAL VOTING RIGHTS | View Document |
| 2025-05-01 | 6-K | NUCALA MATINEE DATA IN COPD PUBLISHED IN NEJM | View Document |
| 2025-05-01 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-04-30 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-04-30 | 6-K | 1ST QUARTER RESULTS | View Document |
| 2025-04-29 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-04-28 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-04-25 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-04-24 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-04-23 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-04-22 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-04-17 | 6-K | BLENREP LICENSED BY UK MHRA | View Document |
| 2025-04-17 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2025-04-17 | 6-K | AREXVY NOW ACIP RECOMMENDED FOR 50-59 AT RIS | View Document |
| 2025-04-17 | 6-K | GSK 5-IN-1 MENINGITIS VACCINE RECOMMENDED IN US | View Document |
| 2025-04-17 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-04-16 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-04-15 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2025-04-15 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-04-14 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2025-04-14 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-04-11 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2025-04-11 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-04-10 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-04-09 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-04-08 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-04-07 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-04-04 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-04-03 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-04-02 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-04-01 | 6-K | TOTAL VOTING RIGHTS | View Document |
| 2025-04-01 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-03-31 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-03-28 | SCHEDULE 13D/A | View Document | |
| 2025-03-28 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2025-03-28 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-03-27 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-03-26 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-03-25 | 6-K | GSK UUTI TREATMENT APPROVED BY US FDA | View Document |
| 2025-03-25 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-03-24 | 6-K | NOTICE OF AGM | View Document |
| 2025-03-24 | 6-K | EMA FILING ACCEPTANCE FOR NUCALA COPD | View Document |
Search company filings and access detailed reports including 10-K, 10-Q, 8-K, and other critical filings. Stay informed on corporate disclosures, regulatory filings, and updates with our easy-to-use EDGAR API filings search tool.
